Instituto Bernabeu Biotech, Avda Albufereta, 31, 03016, Alicante, Spain.
Pharmacogenomics. 2014 Apr;15(6):885-93. doi: 10.2217/pgs.14.49.
Effective controlled ovarian stimulation (COS) is crucial for IVF outcome. Ovarian response to follicle-stimulating hormone, however, varies widely among women undergoing ovarian stimulation. Advance identification of patients who will elicit a poor or high response to standard treatment would be of great clinical benefit for such patients. Application of pharmacogenetics to ovarian response may predict stimulation success but also help in the adjustment and design of doses prior to treatment. Different studies have examined the impact of variations in follicle-stimulating hormone receptor, biochemical pathways involved in estrogen production and action, folliculogenesis and other aspects. Recently, gene-association studies have tried to identify a number of genetic variations affecting interindividual variability in COS.
有效的控制性卵巢刺激（COS）对试管婴儿的结果至关重要。然而，在接受卵巢刺激的女性中，卵巢对卵泡刺激素的反应差异很大。提前识别出对标准治疗反应不佳或反应过高的患者，将对这些患者具有重要的临床意义。将药物遗传学应用于卵巢反应可以预测刺激的成功，同时也有助于在治疗前调整和设计剂量。不同的研究已经研究了卵泡刺激素受体、雌激素产生和作用的生化途径、卵泡发生和其他方面的变化对卵巢刺激的影响。最近，基因关联研究试图确定许多影响 COS 个体间变异性的遗传变异。
